≥80岁病理确诊早期非小细胞肺癌的肺部立体定向放疗:回顾性队列研究
中位生存时间60.0个月,5年局部控制率87.4%、总生存率47.5%;多因素分析显示不可手术和实性结节为总生存不良预测因素。SBRT可行且局部控制好、毒性低。
要点
- ≥80岁病理确诊早期NSCLC患者SBRT后5年局部控制率87.4%、总生存率47.5%。
- 多因素分析显示不可手术与实性结节是SBRT后总生存不良的预测因素。
- 3级放射性肺炎2例(3.1%),5级放射性肺炎1例(1.6%)。
核心结论
- 对于年龄≥80岁且病理确诊早期NSCLC的患者,SBRT可行,局部控制良好且毒性较低。
- SBRT可能使早期NSCLC老年患者获益。
研究设计与样本
- 回顾性队列研究,纳入2009年1月至2020年3月在本机构接受SBRT的年龄≥80岁且病理确诊原发性早期NSCLC患者。
- 采用Kaplan-Meier法估计生存曲线,log-rank检验比较生存曲线,并进行单因素和多因素Cox回归分析,P<0.05为显著。
主要发现
- 中位生存时间为60.0个月(95%CI 43.5-71.1)。
- 1年、3年、5年局部控制率分别为98.4%、90.1%、87.4%。
- 1年、3年、5年肿瘤特异生存率分别为98.4%、93.7%、83.5%。
- 1年、3年、5年无进展生存率分别为81.0%、58.9%、38.2%。
- 1年、3年、5年总生存率分别为88.9%、68.3%、47.5%;多因素分析显示不可手术和实性结节是总生存不良的预测因素。
关键数值与推荐
- SBRT处方剂量为48 Gy分4次或60 Gy分10次。
- 放射性肺炎:3级2例(3.1%),5级1例(1.6%)。
临床怎么用
- 对于年龄≥80岁、病理确诊早期NSCLC且医学上不可手术的患者,可考虑SBRT作为治疗选择。
- 治疗前应关注不可手术状态和实性结节等总生存不良预测因素,并警惕放射性肺炎风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic body radiation therapy (SBRT) is an established therapy for medically inoperable early-stage non-small cell lung cancer (NSCLC). Many elderly patients are medically inoperable owing to comorbidities. Therefore, SBRT may be a useful therapy for elderly patients. However, the application of SBRT for patients aged ≥ 80 years has not been completely elucidated. Therefore, this study aimed to assess the clinical utility of SBRT for elderly patients aged ≥ 80 years with pathologically proven early-stage NSCLC. METHODS: We retrospectively evaluated the data of patients aged ≥ 80 years with pathologically proven primary NSCLC who underwent SBRT at our institution between January 2009 and March 2020. Treatment outcomes and toxicities were analyzed. We used the Kaplan-Meier method to estimate survival curves and the log-rank test to compare the survival curves. We performed univariate and multivariate Cox regression analyses. p-values < 0.05 were regarded significant. RESULTS: Sixty-four patients (65 lesions) were included, and the median follow-up period was 38.7 (range 3.5-95.7) months. The median age was 82.9 (range 80.0-94.8) years. Sixteen patients were medically operable, and 48 patients were medically inoperable. The prescribed dose of SBRT was either 48 Gy in four fractions or 60 Gy in 10 fractions. The median survival time was 60.0 months (95% confidence interval, 43.5-71.1). The 1-, 3-, and 5-year local control, cancer-specific survival, progression-free survival, and overall survival rates were 98.4%, 98.4%, 81.0%, and 88.9%; 90.1%, 93.7%, 58.9%, and 68.3%; and 87.4%, 83.5%, 38.2%, and 47.5%, respectively. Multivariate analysis revealed that inoperability and solid nodules were the predictors of poor overall survival after SBRT in elderly patients. Two patients (3.1%) had grade 3 radiation pneumonitis, and one patient (1.6%) had grade 5 radiation pneumonitis. CONCLUSIONS: SBRT was feasible in patients aged ≥ 80 years with NSCLC. It achieved good local control with minimal toxicity. SBRT may be beneficial in elderly patients with early-stage NSCLC.
引用
- Watanabe K, Katsui K, Sugiyama S, et al. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study. Radiat Oncol. 2021. PMID: 33622369. doi:10.1186/s13014-021-01769-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。